Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22409295 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone, Prednisone or equivalent

Indicates status has not been verified in more than two years